Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Our hypothesis is that treating relapsed or refractory multiple myeloma with PD 0332991
(Palbociclib) in combination with lenalidomide will result will be both effectively inducing
myeloma plasma cell death as well maintaining a favorable side effect profile.